难治性抑郁症的全基因组关联荟萃分析与罕见拷贝数变异分析
该研究基于三个北欧国家数据,采用严格难治性抑郁症(TRD)定义(抗抑郁药治疗失败后接受电休克治疗),比较TRD与健康对照及非TRD患者的常见变异和罕见拷贝数变异。结果显示TRD风险SNP遗传率为26%,发现3号染色体SPATA16内含子区域一个位点,TRD与双相障碍、精神分裂症遗传正相关,且携带更高拷贝数缺失负荷。
要点
- TRD风险SNP遗传率为26%(SE=5%),提示遗传因素参与。
- 发现3号染色体SPATA16内含子区域一个与TRD风险相关的位点。
- TRD与双相障碍(rg=0.86)和精神分裂症(rg=0.57)遗传正相关。
核心结论
- TRD具有遗传基础,其风险与多种精神疾病共享遗传成分,并涉及罕见拷贝数变异负荷增加。
研究设计与样本
- TRD定义为重性抑郁障碍对抗抑郁药多次治疗无反应后接受电休克治疗。
- 分析常见变异(GWAS)和罕见拷贝数变异(CNV)。
主要发现
- TRD风险SNP遗传率为26%(SE=5%)。
- 全基因组关联分析发现3号染色体SPATA16内含子区域一个位点与TRD风险相关。
- TRD风险与双相障碍遗传相关rg=0.86(SE=0.20),与精神分裂症rg=0.57(SE=0.13),与智力负相关rg=-0.13(SE=0.07)。
- PRS分析显示TRD相比非TRD具有更高的多种精神疾病常见变异负荷。
- TRD携带的总CNV缺失负荷和平均长度高于健康对照或非TRD,并与54个已知神经精神CNV相关(ORs=1.74-2.86)。
关键数值与推荐
- TRD风险SNP遗传率26%(SE=5%)。
- 与双相障碍遗传相关0.86(SE=0.20),与精神分裂症0.57(SE=0.13),与智力-0.13(SE=0.07)。
- 54个已知神经精神CNV的OR范围为1.74-2.86。
临床怎么用
- 提示TRD患者可能具有更高的精神疾病遗传负荷,临床评估时可关注共病精神障碍及认知功能。
- 严格定义(含电休克治疗)的TRD可能代表严重亚型,遗传发现需在更广泛TRD人群中验证。
局限性
- TRD定义包含电休克治疗使用,结果可能反映严重形式的治疗抵抗。
- 样本仅来自三个北欧国家,遗传发现的外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment-resistant depression (TRD), defined as major depressive disorder (MDD) with multiple failed responses to antidepressant treatments, has been suggested to be heritable, but identifying its genetic component is challenging. Using a restrictive TRD definition based on antidepressant medication followed by electroconvulsive therapy (ECT), which may represent a severe subset of TRD cases, we investigated both common variants and rare copy number variations (CNVs) associated with a) TRD risk (2 062 TRD vs. 441 037 healthy controls) and b) treatment resistance in MDD (2 062 TRD vs. 38 544 non-TRD) across three Nordic countries. We observed a significant SNP-based heritability for TRD risk at 26% (SE = 5%). Genome-wide association analysis identified one locus on chromosome 3 (intronic region of SPATA16) for TRD risk and one suggestive locus for treatment resistance in MDD. TRD risk showed positive genetic correlations (rg) with other psychiatric disorders, with notably rg with bipolar disorder (0.86, SE = 0.20) and schizophrenia (0.57, SE = 0.13), as well as a negative rg with intelligence (-0.13, SE = 0.07). Analyses using PRS showed that TRD had higher common-variant burdens of various psychiatric disorders compared to non-TRD. Furthermore, TRD carried a higher CNV deletion burden in total and average lengths than healthy controls or non-TRD cases and was associated with a group of 54 known neuropsychiatric CNVs (ORs = 1.74-2.86). Given that our definition of TRD involves the use of ECT, our findings may reflect a severe form of treatment resistance. This work adds evidence on a genetic basis and provides insights into the genetic architecture of TRD, underscoring the need for further genomic research into this 'difficult-to-treat' condition.
引用
- Xiong Y, Krebs K, Jermy B, et al. Genome-wide association meta-analysis and rare copy number variant analysis of treatment-resistant depression. Mol Psychiatry. 2025. PMID: 40571737. doi:10.1038/s41380-025-03084-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。